Goodrx Holdings vs Omnicell
Omnicell is the larger business, with $1.18bn of revenue in fiscal 2025 against $797m for Goodrx Holdings (1.5 times as much). Omnicell grew faster (6.5% against 0.6%). Goodrx Holdings kept more of each dollar of sales as profit: a net margin of 3.8% against 0.2%. Omnicell carries less debt relative to equity (13.6% against 80.3%).
| Latest fiscal year | Goodrx HoldingsGDRX, 2025 | OmnicellOMCL, 2025 |
|---|---|---|
| Revenue | $797m | $1.18bn |
| Revenue growth | 0.6% | 6.5% |
| Net income | $30.4m | $2.1m |
| Operating margin | 11.0% | 0.4% |
| Net margin | 3.8% | 0.2% |
| Return on equity | 4.5% | 0.2% |
| Free cash flow | $164m | $86.9m |
| Cash | $262m | $197m |
| Total debt | $495m | $168m |
| Debt to equity | 80.3% | 13.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $216m | $77.6m |
| Employees | 697 | — |
| Market value | $1.22bn | $1.63bn |
| Price vs our value range | Below our value range | Within our value range |
| Moat score | 28 (Weak) | 50 (Moderate) |
| Insider trades, 12 months | 0 buys, 14 sales | 0 buys, 11 sales |